Lomustine and temozolomide for newly diagnosed glioblastoma with methylated MGMT promoter: Lessons from the CeTeG/NOA-09 trial
Open Access
- 1 December 2019
- journal article
- editorial
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 8 (Suppl 6) , S589-S591
Abstract
Lomustine and temozolomide for newly diagnosed glioblastoma with methylated MGMT promoter: Lessons from the CeTeG/NOA-09 trialKeywords
This publication has 4 references indexed in Scilit:
- Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trialThe Lancet, 2019
- Drug development for glioma: are we repeating the same mistakes?The Lancet Oncology, 2019
- Phase II Trial of Lomustine Plus Temozolomide Chemotherapy in Addition to Radiotherapy in Newly Diagnosed Glioblastoma: UKT-03Journal of Clinical Oncology, 2006
- Effects of carbamoylating agents on tumor metabolismCritical Reviews in Oncology/Hematology, 1987